The U.S. Preventive Services Task Force recently finalized their recommendation that men ages 55 to 69 should speak with their health care providers about prostate cancer screening using the prostate-specific antigen, or PSA. We'll discuss the latest on the procedure, which has a significant problem with false positives. We discuss the latest on the procedure, which has a significant problem with false positives, and hear about developments in research on prostate cancer.
Guests:
Dr. Paul Alpert, clinical professor, department of urology, UCSF Medical Center
Dr. Mark S. Litwin, professor of urology and public health and urology department chair, UCLA
Related Links:
New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients (Urology Journal)